CYTOSORBENTS CORPORATION (CTSO) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -12.93M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 10.57M USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 34.12M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-12.93M | (m) | $10.57M | (m) | $34.12M | (m) |
| 2026-03-31 | $-13.90M | (m) | $10.79M | (m) | $35.36M | (m) |
| 2025-12-31 | $-14.75M | (m) | $10.57M | (m) | $35.65M | (m) |
| 2025-09-30 | $-14.09M | (m) | $10.80M | (m) | $35.11M | (m) |
| 2025-06-30 | $-16.06M | (m) | $11.34M | (m) | $34.76M | (m) |
| 2025-03-31 | $-16.02M | (m) | $10.87M | (m) | $34.14M | (m) |
| 2024-12-31 | $-16.79M | (m) | $10.47M | (m) | $35.00M | (m) |
| 2024-09-30 | $-22.08M | (m) | $14.07M | $9.72M | $32.39M | (m) |
| 2024-06-30 | $-25.10M | (m) | $13.17M | $11.61M | $33.56M | (m) |
| 2024-03-31 | $-28.24M | (m) | $13.18M | $13.76M | $33.70M | (m) |
| 2023-12-31 | $-31.21M | (m) | $13.96M | $15.73M | $33.60M | (m) |
| 2023-09-30 | $-28.22M | (m) | $14.23M | $15.03M | $32.31M | (m) |
| 2023-06-30 | $-29.82M | (m) | $15.52M | $14.58M | $32.88M | (m) |
| 2023-03-31 | $-31.62M | (m) | $15.67M | $15.09M | $33.59M | (m) |
| 2022-12-31 | $-31.52M | (m) | $13.96M | $15.12M | $34.29M | (m) |
| 2022-09-30 | $-34.73M | (m) | $13.45M | $17.85M | $36.78M | (m) |
| 2022-06-30 | $-31.12M | (m) | $11.41M | $18.83M | $35.82M | (m) |
| 2022-03-31 | $-27.68M | (m) | $10.57M | $18.34M | $37.20M | (m) |
| 2021-12-31 | $-22.74M | (m) | $11.05M | $16.38M | $35.75M | (m) |
| 2021-09-30 | $-15.82M | (m) | $10.45M | $12.93M | $33.58M | (m) |
| 2021-06-30 | $-12.37M | (m) | $10.88M | $10.42M | $33.09M | (m) |
| 2021-03-31 | $-10.74M | (m) | $11.42M | $9.13M | $29.86M | (m) |
| 2020-12-31 | $-10.37M | (m) | $11.05M | $8.81M | $28.46M | (m) |
| 2020-09-30 | $-13.17M | (m) | $10.62M | $9.68M | $26.82M | (m) |
| 2020-06-30 | $-16.84M | (m) | $9.43M | $11.11M | $25.65M | (m) |
| 2020-03-31 | $-17.17M | (m) | $8.01M | $11.64M | $23.56M | (m) |
| 2019-12-31 | $-18.97M | (m) | $7.36M | $12.09M | $22.01M | (m) |
| 2019-09-30 | $-19.13M | (m) | $7.35M | $10.96M | $21.82M | (m) |
| 2019-06-30 | $-16.21M | $23.25M | $7.71M | $9.72M | $19.75M | -69.73% |
| 2019-03-31 | $-16.77M | $22.77M | $7.66M | $8.42M | $21.32M | -73.64% |
| 2018-12-31 | $-15.58M | $22.50M | $7.49M | $7.72M | $20.87M | -69.25% |
| 2018-09-30 | $-13.80M | $21.07M | (m) | $7.79M | $18.74M | -65.52% |
| 2018-06-30 | $-13.24M | $19.15M | (m) | $6.49M | $18.28M | -69.15% |
| 2018-03-31 | $-11.39M | $16.96M | (m) | $5.36M | $15.68M | -67.13% |
| 2017-12-31 | $-9.84M | $15.15M | (m) | $4.05M | $14.09M | -64.96% |
| 2017-09-30 | $-10.61M | $13.59M | (m) | $3.29M | $14.06M | -78.07% |
| 2017-06-30 | $-10.60M | $12.18M | (m) | $3.79M | $12.65M | -87.09% |
| 2017-03-31 | $-10.96M | $10.83M | (m) | $4.40M | $11.79M | -101.18% |
| 2016-12-31 | $-11.49M | $9.53M | (m) | $4.78M | $11.10M | -120.62% |
| 2016-09-30 | $-9.58M | $8.21M | (m) | $4.37M | $8.82M | -116.81% |
| 2016-06-30 | $-9.59M | $7.14M | (m) | $4.07M | $8.38M | -134.38% |
| 2016-03-31 | $-9.13M | $5.88M | (m) | $3.78M | $7.38M | -155.32% |
| 2015-12-31 | $-9.30M | $4.79M | (m) | $3.87M | $6.92M | -194.17% |
| 2015-09-30 | $-9.93M | $3.90M | (m) | $3.59M | $6.87M | -254.34% |
| 2015-06-30 | $-9.26M | $3.72M | (m) | $3.60M | $6.41M | -248.81% |
| 2015-03-31 | $-8.84M | $3.78M | (m) | $3.15M | $6.43M | -233.53% |
| 2014-12-31 | $-7.28M | $4.12M | (m) | $2.43M | $5.55M | -176.55% |
| 2014-09-30 | $-5.23M | $4.13M | (m) | $1.50M | $4.15M | -126.64% |
| 2014-06-30 | $-4.42M | $3.85M | (m) | $910.40K | $3.52M | -114.94% |
| 2014-03-31 | $-4.45M | $3.11M | (m) | $1.27M | $2.97M | -142.77% |
| 2013-12-31 | $-4.71M | $2.42M | (m) | $1.74M | $2.58M | -194.55% |
| 2013-09-30 | $-4.52M | $2.15M | (m) | $2.38M | $2.34M | -210.53% |
| 2013-06-30 | $-4.24M | (m) | (m) | $2.55M | $2.01M | (m) |
| 2013-03-31 | $-3.85M | (m) | (m) | $2.60M | $1.70M | (m) |
| 2012-12-31 | $-3.49M | $1.34M | (m) | $2.53M | $1.35M | -259.94% |
| 2012-09-30 | $-3.65M | $774.69K | (m) | $2.35M | (m) | -470.68% |
| 2012-06-30 | $-4.27M | (m) | (m) | $2.58M | (m) | (m) |
| 2012-03-31 | $-4.38M | (m) | (m) | $2.77M | (m) | (m) |
| 2011-12-31 | $-4.44M | $36.08K | (m) | $2.89M | (m) | -12297.71% |
| 2011-09-30 | (m) | (m) | (m) | $2.59M | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | $2.34M | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-2.82M | (m) | (m) | $1.76M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |